Figure 3.

Cumulative probability of death attributed to disease complications/disease progression and to comorbidity by competing risk analysis among 840 patients given a diagnosis of myelodysplastic syndrome at the Department of Hematology and Oncology, Policlinico San Matteo, Pavia Italy, 1992–2007. (A) Patients with refractory anemia or refractory cytopenia with multi-lineage dysplasia according to WHO criteria; (B) Patients with refractory anemia with excess blasts (types 1 and 2). This analysis allows an estimate to be made of the cumulative incidence of a specified failure mode, compared to its competing risk over time.